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Abstract
The role of sirtuin-1 (SIRT1) in innate immunity, and in particular the influence of SIRT1 on antimicrobial defense
against infection, has yet to be reported but is important to define since SIRT1 inhibitors are being investigated as
therapeutic agents in the treatment of cancer, Huntington’s disease, and autoimmune diseases. Given the
therapeutic potential of SIRT1 suppression, we sought to characterize the role of SIRT1 in host defense. Utilizing
both pharmacologic methods and a genetic knockout, we demonstrate that SIRT1 expression has little influence on
macrophage and neutrophil antimicrobial functions. Myeloid SIRT1 expression does not change mortality in gram-
negative toxin-induced shock or gram-positive bacteremia, suggesting that therapeutic suppression of SIRT1 may be
done safely without suppression of myeloid cell-specific immune responses to severe bacterial infections.
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Introduction
Sirtuin 1 (SIRT1) is an evolutionarily conserved member of
the sirtuin family of NAD+-dependent deacetylases. Since their
discovery in 1999, the sirtuins have been the subject of
intensive scientific investigation and discussion. Notably,
SIRT1 was implicated as a mediator of the life-extending
effects of calorie restriction [1–3] and over-expression of SIRT1
was thought to have life-extending effects of its own [4–6]. Both
of these findings have been challenged in subsequent analyses
[7–9] and the true role of SIRT1 in lifespan regulation remains
controversial. Regardless of their life-extending properties,
sirtuins have been shown to play a complex and critical role in
metabolism and cellular stress responses, and as such are
being investigated as therapeutic targets in diabetes,
cardiovascular diseases, inflammatory conditions and
neurodegenerative disorders [10].
Recent evidence has shown that SIRT1 plays a multifaceted
role in adaptive immunity via suppression or amplification of T
and B cell inflammatory responses in a context-dependent
manner. Upregulation of SIRT1 in vitro is associated with T cell
anergy and decreased response to IL-2 [11], but suppression
of SIRT1 promotes the expression of Foxp3 in regulatory T
cells (Tregs), thereby amplifying their immunosuppressive
activity in vitro and in vivo [12,13]. SIRT1 knockout (KO) mice
develop eyelid inflammation in infancy [14], and a lupus-like
nephritis at later ages [15]. However, suppression of SIRT1 in
an established mouse model of lupus (MRL/lrp mice)
decreases autoantibody production and renal pathology [16].
Thus, SIRT1 has complex roles in immune responses and
autoimmunity, and both pharmacologic and genetic tools are
important in delineating the specific inflammatory mechanisms
regulated by SIRT1.
To date, little is known about the function of SIRT1 in innate
immunity and host defense. Whereas several studies have
indicated that SIRT1 suppresses innate inflammatory
responses [17–19] others have reached the opposite
conclusion [20,21]. The influence of SIRT1 on antimicrobial
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defense against infection has yet to be reported but is
important to define, particularly since SIRT1 inhibitors are
being investigated as therapeutic agents for the treatment of
Huntington’s disease and cancer ([22–25]; clinical trials
NCT01521832 and NCT01521585). Other molecular inhibitors
used to treat these disorders have led to immunodeficient
states and increased susceptibility to infection.
Given the previous controversies regarding the role of
sirtuins in mammalian systems, we examined in detail the
consequence of genetic depletion and pharmacological SIRT1
modulation on leukocyte and whole animal responses to
invasive bacterial infection and lipopolysaccharide (LPS)-
induced endotoxemia.
Materials and Methods
Ethics Statement
This study strictly adhered to the recommendations in the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. Ethics approval for animal
experimentation was obtained from the Institutional Animal
Care and Use Committee of the University of California at San
Diego, USA (Protocol Number: s00227m). All efforts were
made to minimize suffering.
Cell Lines, Bacterial Strains, and Reagents
Human-derived HL60 promyelocytic cells and mouse-derived
RAW 264.7 macrophage (Mφ) cell lines (ATCC) were utilized
for in vitro pharmacologic experiments. Cell lines were grown in
RPMI-1640 with 10% FBS at 37°C and 5% CO2. DMSO
(1.25%) was added to the media of HL60 cells 5 days prior to
use in assays to induce neutrophilic differentiation.
Experiments were run in RPMI-1640 with 2% FBS at 37°C and
5% CO2. Group B Streptococcus (GBS) COH1 strain was
grown to mid-log phase (absorbance at 600 nm = 0.4) in Todd-
Hewitt broth (THB) at 37°C, resuspended in PBS to 1 x 108
cfu/ml, and mammalian cells were infected at a multiplicity of
infection (MOI) of 0.5 and 0.1. THB with yeast extract (THY)
was inoculated with Streptococcus pneumoniae (SPN) strain
D39 at a 1:10 dilution, and grown to mid-log phase at 37°C with
5% CO2, resuspended in phosphate-buffered saline (PBS) to 2
x 108 CFU/ml, and mammalian cells were infected at an MOI of
0.1. The putative Sirt-1 activator resveratrol and Sirt-1 inhibitor
sirtinol (Sigma) were used for pharmacologic studies. LPS from
Escherichia coli O111:B4 (Alexis) was used for in vivo
endotoxemia studies. ELISA Duosets from R&D Systems were
utilized for cytokine analysis of serum from mice.
Mouse Strains and Primary Cell Isolation
Myeloid-specific SIRT1 KO (lysMcre Cre+ SIRT1flox/flox) mice
in a C57BL/6 background and WT (lysMcre Cre- SIRT1flox/flox)
mice were used for all experiments. Mice were age (6-9
months) and sex-matched for all experiments. Mice were
sedated with inhaled isoflurane and terminally bled. Blood from
5 mice was pooled for assays. Peritoneal Mφs were isolated by
peritoneal lavage with 10 mL PBS, repeated five times per
mouse, and Mφs were pooled from 3-5 mice. Peritoneal
neutrophils were harvested 4 hours after intraperitoneal (IP)
injection of 500 μL of thioglycolate, in a similar fashion. Alveolar
Mφs were harvested by lavaging the airways five times with
800 μl PBS. Bone marrow (BM) was harvested as previously
described [26]. In brief, femurs and tibias were flushed and BM
was resuspended in water for 10 seconds to lyse red blood
cells. To derive Mφs, BM cells were grown in RPMI-1640 with
20% FBS, 25% L-cell supernatant, 100 IU/ml penicillin, and
100 μg/mL streptomycin at 37°C and 5% CO2. BM Mφs were
harvested with EDTA on day 6 and re-plated at 1 x 105 cells/
well in 96 well plates, and assays were run on day 8. For BM
neutrophils, BM was resuspended with 5 ml PBS and layered
on top of 5 ml each Histopaque 1119 and 1077, spun at 1200
rpm for 30 minutes at RT and the layer of cells at the
intersection of the two Ficoll layers was resuspended in
RPMI-1640 with 5% FBS and 1 μg/ml PMA, plated at 1 x 105
cells per well in 96 well plates, and incubated at 37°C with 5%
CO2 for 10 hours prior to running experiments. Samples of all
myeloid cells (1 x 106 in triplicate) were placed in TRIZOL
(Invitrogen) and frozen at -80°C. Samples were rapidly thawed
and total RNA was isolated using the standard TRIZOL RNA
isolation protocol (Invitrogen). RNA was treated with TURBOTM
RNase-free DNase (Ambion®, Life Technologies) and cDNA
was synthesized from total RNA by iScript cDNA synthesis kit
(BioRad). cDNA underwent quantitative PCR (qPCR) analysis
with SIRT1 primers (Jackson Labs: F and R) using the KAPA
SYBR® FAST qPCR kit (KAPA Biosystems). Efficiencies of all
primers were within 85-100%. mRNA abundance was obtained
by normalizing to beta-tubulin levels.
Bactericidal Assays
HL60 cells, RAW cells, Mφs and neutrophils were plated at 3
x 105 cells/well in 24-well plates (Falcon) the day prior to
infection. For pharmacologic studies, cells were incubated with
increasing concentrations (5, 10, or 20 μM) of resveratrol, a
SIRT1 activator, or sirtinol (10 μM), a SIRT1 inhibitor, for 24
hours prior to infection. At given time points the number of
surviving bacteria in each well (extracellular and intracellular)
was determined by adding triton to a final concentration of
0.025% to each well to lyse mammalian cells, followed by serial
dilution and plating for enumeration of bacteria. Whole blood
assays were done as previously described [27]. In brief, 300 μL
of whole blood was placed in 2 mL siliconized tubes (Fisher)
and 100 μL of log-phase bacteria was added to a final
concentration of 1 x 104 CFU/mL. Tubes were incubated at
37°C on a rotator, and at various time points 25 μL was taken
and serially diluted in sterile water to lyse mammalian cells,
and plated for enumeration of surviving bacteria per mL.
Phagocytosis of SPN was determined by incubating WT and
KO BM Mφs with SPN for one hour at 37°C, rinsing with warm
PBS three times, applying antibiotics (penicillin 10 ug/mL and
gentamycin 100ug/mL) for 60 minutes, followed by rinsing with
warm PBS three times, lysis with 0.025% triton, serial dilution,
plating, and enumeration of CFU. Intracellular killing was done
in a similar manner, except the BM Mφs were infected with
SPN for 3 hours before rinsing and antibiotic treatment.
Percentage of bacteria killed or surviving was calculated
utilizing the CFU in the initial inoculum (time zero), which was
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plated and determined for all experiments. All conditions within
each experiment were done in triplicate and all experiments
were repeated three times.
Gram-positive Bacteremia and Gram-negative
Endotoxemia Models
Myeloid-specific SIRT1 KO (n = 7) and WT mice (n = 5) were
infected with 1 x 105 colony forming units (CFU) of SPN in 400
μL PBS IP as a model of gram-positive bacteremia and sepsis.
For a mouse model of gram-negative endotoxemia and shock,
mice (n = 5 per group) were injected IP with 20 mg/kg LPS in
200 μl PBS. For all in vivo experiments, rectal temperature and
survival were assessed every 8 h, and blood was taken retro-
orbitally via heparinized capillary tubes at 4 and 24 hours. In
vivo challenge experiments were repeated twice.
Statistics
In vitro bactericidal assays were analyzed by one-way
ANOVA with Bonferroni post-tests. In vivo temperature curves
were analyzed by paired one-way ANOVA and Kruskal-Wells
post-tests, while ELISA data on serum was analyzed by two-
way ANOVA. Mortality was analyzed by one-way ANOVA.
Statistical software within GraphPad Prism was used for all
analyses.
Results
Pharmacologic Alteration of SIRT1 Levels Does not
Change Myeloid Cell Killing Capacity
We first sought to define the role of SIRT1 in antimicrobial
activities of myeloid cell lines. Murine Mφs (RAW cells) and
human neutrophil-like cells (HL60s differentiated with 1.25%
DMSO) were infected with GBS, either alone or in the presence
of increasing concentrations (5, 10, or 20 μM) of resveratrol, a
SIRT1 activator, or sirtinol (10 μM), a SIRT1 inhibitor. At 60
minutes, the RAW and HL60 cells had killed 96% and 47% of
the GBS, respectively, and this was not significantly changed
by treatment with resveratrol or sirtinol (Figure 1A). Hence, Mφ
and neutrophil antimicrobial activity is not markedly affected by
pharmacologic activation or inhibition of SIRT1.
SIRT1 Knock-out Efficiency in SIRT1 LysMcre Mouse
Myeloid Cells
qPCR results on total RNA from SIRT1 WT and KO myeloid
cells consistently demonstrate a >90% knock-down efficiency
in the SIRT1 KO cells. In addition, some SIRT1 KO samples
had undetectable levels of SIRT1 RNA, corresponding with a
100% knock-down. Therefore, SIRT1 expression in myeloid
cells in C57BL/6 SIRT1 lysMcre mice is between 0-9%. This
degree of knock-down is comparable to that found in other
lysMcre knock-out mouse strains [1,2].
SIRT1 KO has Little Effect on Antimicrobial Activities of
Macrophages
We next utilized a genetic model to further explore a
potential role of SIRT1 in antimicrobial defense. BM, alveolar,
and peritoneal Mφs were harvested from WT and SIRT1
myeloid KO mice. These Mφ populations represent various
levels of activation, ranging from minimal (BMDM) to highly
activated (peritoneal). Alveolar Mφs were used as mature Mφs
from a tissue site commonly affected by both GBS and SPN.
BMDM from SIRT1 KO mice killed 65% of GBS at 3 hours
compared to 72% killed by WT controls (p = ns, Figure 1B).
When infected with SPN, SIRT1 KO BMDM showed a
significantly reduced level of bacterial killing vs. WT controls
(49% vs. 77%, p < 0.05, Figure 1C). Similarly, peritoneal Mφs
from SIRT1 KO mice showed a killing defect against SPN
bacteria at 1 and 3 hours compared to the WT strains (p <
0.001, Figure 1D). In contrast, no significant defect in SPN
killing was observed in alveolar macrophages (Figure 1E).
Further, SPN growth was similar in whole blood (Figure 1F). To
evaluate the mechanism by which SIRT1 KO BMDM had
decreased killing of SPN, we ran intracellular killing and
phagocytosis assays. SIRT1 KO BMDM had less intracellular
killing of SPN compared to WT (p = 0.0033, Figure 1I), and, as
a mechanism, the SIRT1 KO BMDM had decreased
phagocytosis compared to WT (p < 0.0001, Figure 1I). We thus
conclude loss of SIRT1 has perhaps a modest effect to reduce
Mφ antimicrobial activity via decreased phagocytosis, but that
this effect depends on the type and origin of Mφ and the
bacterial strain.
Neutrophil SIRT1 KOs maintain antimicrobial efficacy
The neutrophil is another important cell in host defense, thus
we utilized our genetic KO mouse model to study the effect of
SIRT1 deficiency on primary neutrophils. BM neutrophils from
WT and SIRT1 myeloid KO mice killed GBS and SPN equally
well (Figure 1G, 1H). We also observed that antimicrobial
activity of peritoneal neutrophils did not differ between WT and
SIRT1 myeloid KO mice (data not shown). We thus conclude
that SIRT1 has no effect on neutrophil antimicrobial activity,
regardless of neutrophil activation state or the bacterial strain,
suggesting that therapeutic suppression of SIRT1 may be
accomplished without provoking increased bacterial
susceptibility.
Myeloid Cell SIRT1 Deficiency does not Impact
Mortality in Models of Gram-negative Endotoxemia or
Gram-positive Bacterial Infection
We next sought to understand the biologic relevance of
SIRT1 in innate immune cells during systemic bacterial
infections. SIRT1 myeloid KO mice injected with LPS were
more resistant to hypothermia than WT mice (31.5°C vs 28.1°C
at 24 hours, p < 0.05, Figure 2A). However, this was not
associated with any survival benefit, as mortality was identical
in the two groups (Figure 2B). Systemic SPN challenge led to
similar mortality curves and hypothermia parameters in WT and
SIRT1 myeloid KO mice (Figure 2C and 2D). Serum levels of
MIP-2, TNFα, and IL-6 were similar at 4 and 24 hours in WT
and SIRT1 KO mice treated with LPS (Figure S1A) and
infected with SPN (Figure S1B). We conclude that while SIRT1
may play minor role in the bactericidal capacity of certain Mφ
populations, overall deletion of SIRT1 in the myeloid lineage
has no effect on survival during gram-positive bacteria
systemic infection or gram-negative endotoxemia.
Myeloid Cell Sirtuin-1 Expression in Host Defense
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Figure 1.  SIRT1 has minimal effects on macrophage and neutrophil antimicrobial function.  Addition of a SIRT1 agonist
(resveratrol) or antagonist (sirtinol) has no effect on the antimicrobial activity of the mouse derived Mφ cell line RAW 264.7 or the
human derived neutrophil-like cell line HL60 (A). Lack of SIRT1 has no effect on BM-derived Mφ killing of GBS (B), but modestly
decreases the ability of BM-derived Mφs to kill SPN (C). IP Mφs lacking SIRT1 demonstrate slightly decreased ability to kill SPN
(D). SIRT1 deficiency does not affect alveolar Mφ antimicrobial activity (E), or change bacterial survival in whole blood (F). SIRT1
deficiency does not change the antimicrobial activity of BM neutrophils against GBS (G) or SPN (H). KO of SIRT1 in BM-derived
Mφs decreases intracellular killing and phagocytosis of SPN (I). Percent bacteria killed or surviving was calculated based on initial
inoculum. All conditions were done in triplicate within each assay, and each assay was repeated three times. Data represent mean
± SD, *p < 0.05, **p = 0.003, *** p < 0.001, **** p < 0.0001.
doi: 10.1371/journal.pone.0084481.g001
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Discussion
We demonstrate here that pharmacologic activation or
inhibition of SIRT1 has no effect on the bacterial killing capacity
of mouse- or human-derived Mφ or neutrophil cell lines. We
also show that SIRT1 deficiency in IP and BM-derived Mφs
modestly decreases their ability to kill SPN, primarily via
reduced phagocytosis. SIRT1 expression has no effect on
neutrophil antimicrobial activity. Finally, we demonstrate that
mice lacking SIRT1 expression in myeloid cells are resistant to
endotoxin-induced hypothermia, but succumb to gram-positive
bacteremia/sepsis and gram-negative endotoxemia/shock with
similar kinetics as WT mice.
Previous groups have shown that resveratrol decreases
LPS-induced TNFα secretion from RAW cells, while sirtinol
amplifies the pro-inflammatory response to LPS [28,29]. In
contrast, resveratrol has been shown to induce apoptosis of
HL60 cells in a dose-dependent manner [30–32]. To our
knowledge, ours is the first study to examine the functional
effects of either molecule on the bacterial killing capacity of
RAW and HL60 cells, and our data indicates that the
antimicrobial properties of these cell lines are largely
independent of SIRT1 expression.
Little is known about the role of SIRT1 in Mφs, and previous
studies have focused on the effects on inflammation rather
than on antimicrobial functions. For example, suppression of
SIRT1 has been shown to increase Mφ infiltration into inflamed
tissues in mouse models of diabetes and colitis [33,34],
perhaps by increased NFkB activity [19] and increased
expression of MMP9 [35]. Less is know about SIRT1 activity in
neutrophils. SIRT1 expression is decreased in neutrophils
differentiated from acute promyelocytic leukemia cells [36],
suggesting that it may be expressed at low levels in this cell
type.
We utilized the Cre-loxP system [37] to target SIRT1 in
myeloid cells alone as the global KO of SIRT1 is embryonic
lethal [14,38]. Specifically, we utilized SIRT1flox/flox Cre+ mice as
our KO and SIRT1flox/flox Cre- mice as our WT control.
Theoretically, the loxP sites are within introns and therefore do
not interfere with the normal function of the SIRT1 gene.
Figure 2.  SIRT1 deficiency in myeloid cells has no effect on mortality due to gram-negative endotoxemia or gram-positive
bacteremia.  SIRT1 myeloid KO mice were more resistant to hypothermia in the face of LPS challenge than WT mice (A), however
mortality was identical in the two groups (B; n = 5 mice per group). SIRT1 myeloid KO mice demonstrated no difference in
temperature response (C) or mortality (D) due to gram-positive bacterial infection (n = 5 WT and 7 KO mice). In vivo experiments
were repeated twice. Data represent mean ± SD, *p < 0.05.
doi: 10.1371/journal.pone.0084481.g002
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However double-floxing of alleles can have an effect on
expression, and thus Cre- mice in a double-floxed mouse may
have different findings than a non-floxed C57BL/6 mouse. In
addition, Cre expression is driven by the lysozyme promoter
and thus should be specific to myeloid cells, thus Cre+
SIRT1flox/flox mice should only be different from Cre- SIRT1flox/flox
mice in that they don’t express SIRT1. However, Cre
expression alone can affect cell physiology when expressed
highly, and possibly could recognize genomic sequences that
resemble loxP sites to cause DNA damage. Thus Cre+ non-
floxed mice may behave differently than Cre- non-floxed or
Cre- SIRT1flox/flox mice (Jackson Labs).
Despite mildly decreasing Mφ antimicrobial activity and
affording resistance to endotoxin-induced hypothermia, SIRT1
expression had no effect on mortality due to gram-positive
infection or endotoxemia. Redundancy within the sirtuin family
may explain this finding. For example, SIRT6 is upregulated in
BMDM from SIRT1 KO mice, and is bound to NF-κB
transcriptional regulatory elements [17]. Our findings
emphasize the importance of examining both in vitro and in
vivo effects of, and both inflammatory and antimicrobial
responses to, potential immune mediators such as SIRT1.
SIRT1 is under investigation as a therapeutic target in
metabolic, cardiovascular, neurodegenerative and metastatic
diseases. Given the emerging medicinal potential of this
molecule, we studied its role in host innate defense and have
demonstrated that therapeutic suppression of SIRT1 might be
accomplished with limited effects on the host myeloid cell
response to bacterial infections.
Supporting Information
Figure S1.  Sirtuin1 lysMcre Cre+ KO (SIRT1 KO) and
lysMcre Cre- (WT) control mice were injected with LPS i.p.
in a gram-negative model of sepsis. Mice were bled via
accessing the retro-orbital vein at 4 and 24 hours with
heparinized capillary tubes. The blood was spun at 1600rpm
for 15 minutes and serum was frozen at -80°C until being
diluted 1:10 for ELISAs (R&D Systems Duosets). Serum levels
of MIP-2, TNFα, and IL-6 were similar at 4 and 24 hours in WT
and SIRT1 KO mice (A). Mice were infected with SPN i.p. in a
gram-positive model of sepsis. Serum levels of MIP-2, TNFα,
and IL-6 were similar at 4 and 24 hours in WT and SIRT1 KO
mice (B). All serum samples from individual mice were tested in
triplicate.
(TIFF)
Author Contributions
Conceived and designed the experiments: LECA VN LG AMT
AEL. Performed the experiments: LECA AMT AEL. Analyzed
the data: LECA VN LG BJM AEL. Contributed reagents/
materials/analysis tools: LECA VN LG BJM KZ AC. Wrote the
manuscript: LECA VN LG BJM. Made the knock-out mouse
utilized in the studies: KZ AC LG.
References
1. Choi SH, Wiesner P, Almazan F, Kim J, Miller YI (2012) Spleen
tyrosine kinase regulates AP-1 dependent transcriptional response to
minimally oxidized LDL. PLOS ONE 7: e32378. doi:10.1371/
journal.pone.0032378. PubMed: 22384232.
2. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Mönch K, Thoren
LA et al. (2008) NMD is essential for hematopoietic stem and
progenitor cells and for eliminating by-products of programmed DNA
rearrangements. Genes Dev 22: 1381-1396. doi:10.1101/gad.468808.
PubMed: 18483223.
3. Kassotis J, Sauberman RB, Cabo C, Wit AL, Coromilas J (2003) Beta
receptor blockade potentiates the antiarrhythmic actions of d-sotalol on
reentrant ventricular tachycardia in a canine model of myocardial
infarction. J Cardiovasc Electrophysiol 14: 1233-1244. doi:10.1046/j.
1540-8167.2003.02413.x. PubMed: 14678141.
4. Tissenbaum HA, Guarente L (2001) Increased dosage of a sir-2 gene
extends lifespan in Caenorhabditis elegans. Nature 410: 227-230. doi:
10.1038/35065638. PubMed: 11242085.
5. Hangai-Hoger N, Cabrales P, Briceño JC, Tsai AG, Intaglietta M (2004)
Microlymphatic and tissue oxygen tension in the rat mesentery. Am J
Physiol Heart Circ Physiol 286: H878-H883. PubMed: 14630627.
6. Briceño JC, Cabrales P, Tsai AG, Intaglietta M (2004) Radial
displacement of red blood cells during hemodilution and the effect on
arteriolar oxygen profile. Am J Physiol Heart Circ Physiol 286: H1223-
H1228. PubMed: 14615279.
7. Radhakrishnan K, LaManna JC, Cabrera ME (2003) A quantitative
study of oxygen as a metabolic regulator. Adv Exp Med Biol 530:
547-554. doi:10.1007/978-1-4615-0075-9_52. PubMed: 14562750.
8. Fregosi RF, Quan SF, Kaemingk KL, Morgan WJ, Goodwin JL et al.
(2003) Sleep-disordered breathing, pharyngeal size and soft tissue
anatomy in children. J Appl Physiol (1985) 95: 2030-2038. PubMed:
12897029.
9. Caballero B, Himes JH, Lohman T, Davis SM, Stevens J et al. (2003)
Body composition and overweight prevalence in 1704 schoolchildren
from 7 American Indian communities. Am J Clin Nutr 78: 308-312.
PubMed: 12885714.
10. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) Are
sirtuins viable targets for improving healthspan and lifespan? Nat Rev
Drug Discov 11: 443-461. doi:10.1038/nrd3738. PubMed: 22653216.
11. Cabell CH, Abrutyn E, Karchmer AW (2003) Cardiology patient page.
Bacterial endocarditis: the disease, treatment, and prevention.
Circulation 107: e185-e187. PubMed: 12777321.
12. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM et
al. (2010) Regulation of Treg functionality by acetylation-mediated
Foxp3 protein stabilization. Blood 115: 965-974. doi:10.1182/
blood-2009-02-207118. PubMed: 19996091.
13. Beier UH, Wang L, Bhatti TR, Liu Y, Han R et al. (2011) Sirtuin-1
targeting promotes Foxp3+ T-regulatory cell function and prolongs
allograft survival. Mol Cell Biol 31: 1022-1029. doi:10.1128/MCB.
01206-10. PubMed: 21199917.
14. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K et al.
(2003) The mammalian SIR2alpha protein has a role in embryogenesis
and gametogenesis. Mol Cell Biol 23: 38-54. doi:10.1128/MCB.
23.1.38-54.2003. PubMed: 12482959.
15. Sequeira J, Boily G, Bazinet S, Saliba S, He X et al. (2008) sirt1-null
mice develop an autoimmune-like condition. Exp Cell Res 314:
3069-3074. doi:10.1016/j.yexcr.2008.07.011. PubMed: 18687325.
16. Hu N, Long H, Zhao M, Yin H, Lu Q (2009) Aberrant expression pattern
of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA
in MRL/lpr mice. Scand J Rheumatol 38: 464-471. doi:
10.3109/03009740902895750. PubMed: 19922023.
17. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW et al. (2010)
Myeloid deletion of SIRT1 induces inflammatory signaling in response
to environmental stress. Mol Cell Biol 30: 4712-4721. doi:10.1128/
MCB.00657-10. PubMed: 20647536.
18. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A et al. (2007)
Sirtuin regulates cigarette smoke-induced proinflammatory mediator
release via RelA/p65 NF-kappaB in macrophages in vitro and in rat
lungs in vivo: implications for chronic inflammation and aging. Am J
Physiol Lung Cell Mol Physiol 292: L567-L576. PubMed: 17041012.
19. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N et al.
(2010) SIRT1 inhibits inflammatory pathways in macrophages and
Myeloid Cell Sirtuin-1 Expression in Host Defense
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e84481
modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298:
E419-E428. doi:10.1152/ajpendo.00417.2009. PubMed: 19996381.
20. Fernandes CA, Fievez L, Neyrinck AM, Delzenne NM, Bureau F et al.
(2012) Sirtuin inhibition attenuates the production of inflammatory
cytokines in lipopolysaccharide-stimulated macrophages. Biochem
Biophys Res Commun 420: 857-861. doi:10.1016/j.bbrc.2012.03.088.
PubMed: 22469470.
21. Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ et al. (2010) SIRT1
suppresses activator protein-1 transcriptional activity and
cyclooxygenase-2 expression in macrophages. J Biol Chem 285:
7097-7110. doi:10.1074/jbc.M109.038604. PubMed: 20042607.
22. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P et al. (2009)
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic
effect. Oncogene 28: 781-791. PubMed: 19060927.
23. Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M et al. (2012)
High expression of the longevity gene product SIRT1 and apoptosis
induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 131:
2044-2055. doi:10.1002/ijc.27481. PubMed: 22322739.
24. Li L, Wang L, Wang Z, Ho Y, McDonald T et al. (2012) Activation of p53
by SIRT1 inhibition enhances elimination of CML leukemia stem cells in
combination with imatinib. Cancer Cell 21: 266-281. doi:10.1016/j.ccr.
2011.12.020. PubMed: 22340598.
25. Zhang Q, Zeng SX, Zhang Y, Ding D, Ye Q et al. (2012) A small
molecule Inauhzin inhibits SIRT1 activity and suppresses tumour
growth through activation of p53. EMBO molecular medicine 4:
298-312.
26. Mbaruku G, Vork F, Vyagusa D, Mwakipiti R, van Roosmalen J (2003)
Estimates of maternal mortality in western Tanzania by the sisterhood
method. Afr J Reprod Health 7: 84-91. doi:10.2307/3583293. PubMed:
15055151.
27. Cabana VG, Feng N, Reardon CA, Lukens J, Webb NR et al. (2004)
Influence of apoA-I and apoE on the formation of serum amyloid A-
containing lipoproteins in vivo and in vitro. J Lipid Res 45: 317-325.
PubMed: 14595002.
28. Mwangangi JM, Mbogo CM, Nzovu JG, Githure JI, Yan G et al. (2003)
Blood-meal analysis for anopheline mosquitoes sampled along the
Kenyan coast. J Am Mosq Control Assoc 19: 371-375. PubMed:
14710739.
29. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L et al. (2009) Role of
SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-
alpha production in cultured macrophage cell lines. Am J Physiol
Gastrointest Liver Physiol 296: G1047-G1053. doi:10.1152/ajpgi.
00016.2009. PubMed: 19299582.
30. Clément MV, Hirpara JL, Chawdhury SH, Pervaiz S (1998)
Chemopreventive agent resveratrol, a natural product derived from
grapes, triggers CD95 signaling-dependent apoptosis in human tumor
cells. Blood 92: 996-1002. PubMed: 9680369.
31. Stervbo U, Vang O, Bonnesen C (2006) Time- and concentration-
dependent effects of resveratrol in HL-60 and HepG2 cells. Cell Prolif
39: 479-493. doi:10.1111/j.1365-2184.2006.00406.x. PubMed:
17109633.
32. Cakir Z, Saydam G, Sahin F, Baran Y (2011) The roles of bioactive
sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid
leukemia cells. J Cancer Res Clin Oncol 137: 279-286. doi:10.1007/
s00432-010-0884-x. PubMed: 20401667.
33. Lee SM, Yang H, Tartar DM, Gao B, Luo X et al. (2011) Prevention and
treatment of diabetes with resveratrol in a non-obese mouse model of
type 1 diabetes. Diabetologia 54: 1136-1146. doi:10.1007/
s00125-011-2064-1. PubMed: 21340626.
34. Singh UP, Singh NP, Singh B, Hofseth LJ, Price RL et al. (2010)
Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type
information regulation-1 and down-regulates nuclear transcription
factor-kappaB activation to abrogate dextran sulfate sodium-induced
colitis. J Pharmacol Exp Ther 332: 829-839. doi:10.1124/jpet.
109.160838. PubMed: 19940103.
35. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M et al. (2009) A
protein deacetylase SIRT1 is a negative regulator of
metalloproteinase-9. FASEB Journal : Official Publication of the
Federation of American Societies for Experimental Biology 23:
2810-2819. doi:10.1096/fj.08-125468.
36. Wampfler J, Tschan MP, Shan D, Laemmle A, Leibundgut EO et al.
(2009) SIRT1 is downregulated during neutrophil differentiation of acute
promyelocytic leukaemia cells. Br J Haematol 146: 337-341. doi:
10.1111/j.1365-2141.2009.07749.x. PubMed: 19466968.
37. Hoess RH, Ziese M, Sternberg N (1982) P1 site-specific recombination:
nucleotide sequence of the recombining sites. Proc Natl Acad Sci U S
A 79: 3398-3402. doi:10.1073/pnas.79.11.3398. PubMed: 6954485.
38. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y et al. (2003)
Developmental defects and p53 hyperacetylation in Sir2 homolog
(SIRT1)-deficient mice. Proc Natl Acad Sci U S A 100: 10794-10799.
doi:10.1073/pnas.1934713100. PubMed: 12960381.
Myeloid Cell Sirtuin-1 Expression in Host Defense
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e84481
